rs2108225 — SLC26A3 SLC26A3 Ulcerative Colitis Susceptibility Variant

SLC26A3 — The Intestinal Chloride Pump at the Heart of Mucosal Immunity

The SLC26A3 gene¹¹ SLC26A3 gene
Solute Carrier Family 26 Member 3, also known as DRA (Down-Regulated in Adenoma) — a chloride/bicarbonate antiporter expressed at the apical membrane of intestinal epithelial cells and goblet cells encodes the intestine's primary chloride-absorbing transporter. By exchanging luminal chloride for intracellular bicarbonate across the apical membrane of colonocytes and goblet cells, SLC26A3 simultaneously drives chloride absorption and maintains the alkaline surface pH that protects the mucus layer, shapes the colonic microbiome, and gates mucosal immune activation. rs2108225 is a regulatory tag SNP²² regulatory tag SNP
A non-coding variant approximately 9 kb downstream of the SLC26A3 transcription end site — identified in a GWAS; likely in LD with a functional variant affecting SLC26A3 expression or regulation in intestinal tissue at the SLC26A3 locus identified in the first large-scale GWAS of ulcerative colitis in a Japanese population.

The Mechanism

SLC26A3/DRA operates as a Cl⁻/HCO₃⁻ antiporter³³ Cl⁻/HCO₃⁻ antiporter
An antiporter moves two ions in opposite directions across the membrane simultaneously; DRA imports Cl⁻ while exporting HCO₃⁻, coupling chloride absorption to bicarbonate secretion on the apical (luminal) surface of intestinal epithelial cells. This exchange serves three interlocking functions: it absorbs chloride from the intestinal lumen (preventing chloride diarrhea), it secretes bicarbonate into the mucus layer (alkalinizing the mucosal surface pH), and — in goblet cells — it drives the bicarbonate-dependent expansion of mucin glycoproteins that form the mucus barrier.

When SLC26A3 activity is reduced, these three processes fail together. Studies in DRA-knockout and TNF-α-overexpressing mouse models⁴⁴ Studies in DRA-knockout and TNF-α-overexpressing mouse models
Xiao et al. used TNF-α-transgenic mice with documented DRA downregulation; DRA null mice show severe chloride diarrhea with absent colonic bicarbonate secretion demonstrate that even mild colonic inflammation is sufficient to severely deplete DRA expression, producing a "strong defect in ileocolonic bicarbonate secretion" independent of changes to other ion transporters (CFTR, NHE3, NBC). The resulting acidified mucus layer creates a hostile environment for protective commensal bacteria that depend on alkaline pH, while favouring acid-tolerant pathobionts. A thinner, less-expanded mucus layer then exposes the epithelium directly to luminal microbial products, triggering pattern-recognition receptor activation and NF-κB-driven cytokine release.

The loop closes via reciprocal TNF-α/DRA regulation⁵⁵ reciprocal TNF-α/DRA regulation
DRA knockdown increases TNF-α secretion from intestinal cells; TNF-α in turn dose-dependently suppresses DRA expression — a bidirectional circuit that can sustain mucosal inflammation once initiated. TNF-α suppresses DRA expression in intestinal epithelial cells, and DRA silencing elevates TNF-α secretion in the same cells. Risk allele carriers at rs2108225 may start with constitutively lower SLC26A3 expression or a steeper inflammatory-suppression response, making it easier for this feedback loop to become self-sustaining.

The Evidence

The primary evidence comes from a two-stage Japanese genome-wide association study⁶⁶ two-stage Japanese genome-wide association study
Asano et al. (2009): Stage 1 — 1,384 UC cases and 3,057 controls on the Illumina Human610-Quad BeadChip; Stage 2 — independent replication cohort by Asano et al. (2009), which genotyped 1,384 Japanese individuals with ulcerative colitis and 3,057 controls across approximately 590,000 SNPs. The SLC26A3 locus reached genome-wide suggestive significance at p = 9.50 × 10⁻⁸ with an odds ratio of 1.32 (95% CI 1.19–1.47) per risk A allele — ranking it alongside FCGR2A and a chromosome 13q12 locus as one of three novel UC susceptibility signals identified in that study.

A Chinese case-control study⁷⁷ Chinese case-control study
Shao et al. (2018) in International Journal of Colorectal Disease: 5 SLC26A3 polymorphisms typed in Chinese UC patients and healthy controls using SNaPshot genotyping; colonic tissue DRA expression assessed by qRT-PCR and immunohistochemistry confirmed that rs2108225 variation in SLC26A3 increases UC risk and is associated with altered DRA mRNA and protein expression in colonic tissue from UC patients, providing functional support for the GWAS finding. The mechanistic studies on DRA downregulation (PMIDs 21557395, 29286110) were conducted in cell and animal systems and are therefore indirect but biologically coherent evidence for the pathway.

The SLC26A3 UC signal has not been consistently replicated in large European IBD GWAS meta-analyses, which may reflect population-specific linkage disequilibrium patterns — the causal variant(s) at the locus may be in strong LD with rs2108225 in East Asian populations but not in Europeans.

Practical Actions

For risk A allele carriers, the actionable implication centres on protecting mucosal bicarbonate secretion and the gut epithelial barrier. Short-chain fatty acids (SCFAs)⁸⁸ Short-chain fatty acids (SCFAs)
Butyrate produced by colonic fermentation of dietary fibre upregulates DRA expression in intestinal epithelial cells via histone deacetylase inhibition, directly increasing SLC26A3 activity — particularly butyrate — directly upregulate DRA expression in colonocytes, offering a dietary lever to compensate for genetically reduced SLC26A3 activity. Fermentable dietary fibre (inulin, resistant starch, pectin) that drives butyrate production by gut bacteria is a concrete, mechanism-specific intervention for this locus.

All-trans retinoic acid (ATRA)⁹⁹ All-trans retinoic acid (ATRA)
The active form of vitamin A; it upregulates DRA by blocking IFN-γ-induced STAT1 phosphorylation, counteracting a key inflammatory suppression pathway for SLC26A3 blocks the IFN-γ/STAT1 pathway that suppresses DRA during inflammation, directly preserving SLC26A3 expression under inflammatory conditions. Adequate vitamin A status supports this ATRA-dependent DRA maintenance pathway.

Interactions

The three UC susceptibility loci identified by Asano et al. (rs2108225 at SLC26A3, rs1801274 at FCGR2A, and rs17085007 at 13q12) represent distinct biological pathways — innate epithelial barrier (SLC26A3), immunoglobulin receptor signalling (FCGR2A), and an unknown locus (13q12). Their combined contribution to UC risk is additive rather than synergistic, and no compound effect has been characterised in published literature.